cas 6704-31-0|| where to buy oxetan-3-one

Nom du produit:oxetan-3-one

IUPAC Name:oxetan-3-one

Unité d'emballage	Stock disponible	Prix($)
CM104041-100g	in stock	ƛƿȐ
CM104041-500g	in stock	ȡȐƛ
CM104041-1000g	in stock	Ƕǜƿ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 6704-31-0 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:6704-31-0; Formule moléculaire:C3H4O2; Point de fusion:-; Code SMILES:O=C1COC1; Densité:

: Numéro de catalogue:CM104041; Poids moléculaire:72.06; Point d'ébullition:; N° Mdl:MFCD09263255; Stockage:

: Oxetanes; Oxygen heterocycles are one of the most common heterocycles in drugs and natural products. Oxetene has high polarity and is also a good acceptor for hydrogen bond, which contributes to the metabolism and chemical stability of its host molecules. When substituted for commonly used functional groups such as gem dimethyl or carbonyl, oxetane units can induce profound changes in water solubility, lipophilicity, metabolic stability and conformational preference. Four of the FDA-approved drugs contain oxetenes: Orlistat, Paclitaxel, and two of its derivatives, Docetaxel and Cabazitaxel. Currently, oxetane-containing building blocks are flourishing in medicinal chemistry and drug discovery.

: Alicyclic Heterocycles; When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.

: Fenebrutinib; Roche’s investigational drug, Fenebrutinib has shown brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (MS) from the recent release of new data from Phase II FENopta study. Fenebrutinib is a potent and highly selective Bruton’s tyrosine kinase (BTK) inhibitor, and currently the only reversible inhibitor being tested in Phase III MS trials. BTK inhibitor is involved in key pathological features of MS, including B-cell development and activation.